Evidence map›Paper›PMID 33182705›Full record

ArticleMolecules (Basel, Switzerland)2020

Circulating Ligands of the Receptor for Advanced Glycation End Products and the Soluble Form of the Receptor Modulate Cardiovascular Cell Apoptosis in Diabetes.

James N Tsoporis, Erifili Hatziagelaki, Sahil Gupta, Shehla Izhar, Vasileos Salpeas, Anastasia Tsiavou, Angelos G Rigopoulos, Andreas S Triantafyllis, John C Marshall, Thomas G Parker and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

James N TsoporisKeenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, Unity Health Toronto, University of Toronto, Toronto, ON M5B 1T8, Canada.
Erifili HatziagelakiDepartment of Internal Medicine, Research Institute and Diabetes Center, Attikon University Hospital, University of Athens Medical School, 124 62 Athens, Greece.
Sahil GuptaKeenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, Unity Health Toronto, University of Toronto, Toronto, ON M5B 1T8, Canada.
Shehla IzharKeenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, Unity Health Toronto, University of Toronto, Toronto, ON M5B 1T8, Canada.
Vasileos SalpeasAcademic Department of Cardiology, Attikon University Hospital, University of Athens Medical School, 12462 Athens, Greece.
Anastasia TsiavouDepartment of Internal Medicine, Research Institute and Diabetes Center, Attikon University Hospital, University of Athens Medical School, 124 62 Athens, Greece.
Angelos G RigopoulosAcademic Department of Cardiology, Attikon University Hospital, University of Athens Medical School, 12462 Athens, Greece.ORCID 0000-0003-0735-2319
Andreas S TriantafyllisAcademic Department of Cardiology, Attikon University Hospital, University of Athens Medical School, 12462 Athens, Greece.
John C MarshallKeenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, Unity Health Toronto, University of Toronto, Toronto, ON M5B 1T8, Canada.
Thomas G ParkerKeenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, Unity Health Toronto, University of Toronto, Toronto, ON M5B 1T8, Canada.
Ioannis K RizosAcademic Department of Cardiology, Attikon University Hospital, University of Athens Medical School, 12462 Athens, Greece.
National and Kapodistrian University of Athens · GRUniversity of Toronto · CA

Funding

CIHR MOP-111066Heart and Stroke Foundation of Canada NA-7276
6 · The paper itself

Abstract

We determined whether plasma concentrations of the receptor for advanced glycation end products (RAGE) and the soluble (s) form of RAGE (sRAGE) in healthy individuals and patients with type 2 diabetes (T2D) modulate vascular remodeling. Healthy individuals and patients with T2D were divided into two age groups: young = <35 years old or middle-aged (36-64 years old) and stratified based on normal glucose tolerance (NGT), impaired (IGT), and T2D. Plasma titers of sRAGE, the RAGE ligands, AGEs, S100B, S100A1, S100A6, and the apoptotic marker Fas ligand Fas(L) were measured by enzyme-linked immunosorbent assay (ELISA). The apoptotic potential of the above RAGE ligands and sRAGE were assessed in cultured adult rat aortic smooth muscle cells (ASMC). In NGT individuals, aging increased the circulating levels of AGEs and S100B and decreased sRAGE, S100A1 and S100A6. Middle-aged patients with T2D presented higher levels of circulating S100B, AGEs and FasL, but lower levels of sRAGE, S100A1 and S100A6 than individuals with NGT or IGT. Treatment of ASMC with either AGEs or S100B at concentrations detected in T2D patients increased markers of inflammation and apoptosis. Responses attenuated by concomitant administration of sRAGE. In middle-aged patients with T2D, lower circulating plasma levels of sRAGE may limit decoy and exogenous trapping of deleterious pro-apoptotic/pro-inflammatory RAGE ligands AGEs and S100B, increasing the risk for diabetic complications.

Indexed as

ApoptosisLigandsAdultAgedAge FactorsAnimalsAnthropometryCell Cycle ProteinsCells, CulturedDiabetes Mellitus, Type 2Endothelium, VascularFas Ligand Proteinfas ReceptorFemaleGlucose Tolerance TestHumansAGER protein, humanCell Cycle ProteinsFASLG protein, humanFas Ligand ProteinFAS protein, humanfas ReceptorLigandsReceptor for Advanced Glycation End ProductsS100A1 proteinS100A6 protein, humanS100B protein, humanS100 Calcium Binding Protein A6S100 Calcium Binding Protein beta SubunitS100 Proteinsapoptosisdiabetesreceptor for advanced glycation end productsS100 proteins

Identifiers

PMID33182705
PMCPMC7696395
OpenAlexW3102587288

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.